Showing 2851-2860 of 3039 results for "".
- CorNeat Vision Completes Preclinical Phase For Synthetic Cornea and Scleral Patchhttps://modernod.com/news/corneat-vision-completes-preclinical-phase-for-synthetic-cornea-and-scleral-patch/2479538/CorNeat Vision announced it has completed the preclinical stage of its cornea implant (CorNeat KPro/Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch). The company’s solutions, which also include a glaucoma drainage device, the CorNeat eShunt, will b
- Genentech to Present Pivitol Data for Satralizumab in Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/genentech-to-present-pivitol-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder/2476853/Genentech announced that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 11-13 in Stockholm. Presentations include complete phase 3 results from the SAkuraS
- Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russiahttps://modernod.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia. Terms of the deal were not disc
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at EURETINAhttps://modernod.com/news/allegro-ophthalmics-to-present-the-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-euretina/2476845/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the European Society of Retina Specialists (EURETINA) Congress that is being
- Japan Conducts World’s First Transplant With iPS Cells for Corneal Diseasehttps://modernod.com/news/japan-conducts-worlds-1st-transplant-with-ips-cells-for-corneal-disease/2476836/A research team from Japan’s Osaka University said Thursday that it has conducted the world’s first transplant for corneal disease using induced pluripotent stem (iPS) cells. The team conducted the surgery in July, allowing iPS corneal tissues to replace the current queuing for cornea
- Topcon Launches the Maestro2 with Automated OCTAhttps://modernod.com/news/topcon-launches-the-maestro2-with-automated-octa/2476826/Topcon has announced the launch of the Maestro2 Automated OCT/Fundus Camera, now with OCTA. Building on the success of its predecessor, the 3D OCT-1 Maestro, the new Maestro2 adds even more clinical utility to its multimodality platform, according to a company news release. The Maestro2 is
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5
- TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidatehttps://modernod.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/TopiVert Pharma announced topline results from THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1, a multicenter, randomized, double-masked, placebo-controlled phase 2b/3
- Bausch + Lomb Showcases New Retina Innovations at In-Booth Wet Lab at ASRShttps://modernod.com/news/bausch-lomb-showcases-new-retina-innovations-at-in-booth-wet-lab-at-asrs/2476764/Bausch + Lomb announced that it will showcase the company’s latest retina innovations, including the 23-gauge Bi-Blade dual port vitrectomy cutter and the FreeFlow infusion system, at a wet lab located in the Bausch + Lomb booth (#606) during the Annual Meeting of the American Society of Retina S
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates